A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer

Trial Details

NCT ID

NCT06830850

Phase

PHASE1

Sponsor

Atridia Pty Ltd.

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

• HRS-5041 Single dose of HRS-5041 orally administered

Locations (sample)

• Sydney, New South Wales, Australia|-33.86785,151.20732
• Sydney, New South Wales, Australia|-33.86785,151.20732
• Adelaide, South Australia, Australia|-34.92866,138.59863
• Adelaide, South Australia, Australia|-34.92866,138.59863
• Brisbane, Australia|-27.46794,153.02809

Key Eligibility Criteria

• Ability to understand the trial procedures and possible adverse events, voluntarily participate in the trial.
• Adequate bone marrow and other vital organ functions
• Adequate liver function tests
• Metastatic Castration-resistant Prostate Cancer

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.